The 10 identified clinical tier I–II variants were detected in 6 out of the 11 analyzed genes (TP53, KRAS, BRAF, CDKN2A, GNAS, and RNF43) and were all exclusive for DF samples; 30% (3/10) of the clinical tier I–II variants were in the KRAS or TP53 genes, followed by 10% (1/10) in the BRAF, CDKN2A, GNAS, and RNF43 genes. This evidence concerns the gene CDKN2A and dengue disease.